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Technologies for genome-wide sequence interrogation have dramatically improved our ability to
identify loci associated with complex human disease. However, a chasm remains between correla-
tions and causality that stems, in part, from a limiting theoretical framework derived fromMendelian
genetics and an incomplete understanding of disease physiology. Here we propose a set of criteria,
akin to Koch’s postulates for infectious disease, for assigning causality between genetic variants
and human disease phenotypes..Thus it is easy to prove that the wearing of tall hats and the carrying of
umbrellas enlarges the chest, prolongs life, and confers comparative immunity
from disease; for the statistics show that the classes which use these articles
are bigger, healthier, and live longer than the class which never dreams of pos-
sessing such things. It does not take much perspicacity to see that what really
makes this difference is not the tall hat and the umbrella, but the wealth and nour-
ishment of which they are evidence, and that a gold watch or membership of a
club in Pall Mall might be proved in the same way to have the like sovereign
virtues..
George Bernard Shaw, The Doctor’s Dilemma (Preface), 1909Distinguishing correlation from causality
is the essence of experimental science.
Nowhere is the need for this distinction
greater today than in complex disease ge-
netics, where proof that specific genes
have causal effects on human disease
phenotypes remains an enormous burden
and challenge. Given the potential scienti-
fic and medical payoffs of disease gene
discovery (Chakravarti, 2001), we argue
in this Essay of the need for a rigorous ex-
amination of the assumptions under
which we connect genes to phenotypes.
This is particularly so in this age of routine
-omic surveys, which can produce more
false-positive than true-positive findings
(Kohane et al., 2006). Moreover, genomic
mapping and sequencing approaches
that are invaluable for producing a list of
unbiased candidates are, by themselves,
insufficient for implicating specific gene(s)
in a disease or biological process. Conse-
quently, we suggest that specific genetic
criteria, analogous to Koch’s postulates
in microbiology, need to be satisfied in or-der to promote the role of one or more
genes as being ‘‘causal,’’ rather than just
‘‘associated,’’ in a disease process
(Brown and Goldstein, 1992; Falkow,
1988, 2004) (Box 1).
Below we discuss the nature of the
‘‘proof’’ that we desire in order to make
fundamental discoveries in human path-
ophysiology. We admit at the outset
that the answers are not straightforward,
and that there are serious technical
and intellectual impediments to demon-
strating causality for the common com-
plex disorders of man where multiple
interacting genes are involved. We
acknowledge that even unproven candi-
date genes may lead to significant
insight into disease pathophysiology.
Nevertheless, the casual conflation of
‘‘mapped locus’’ to ‘‘proven gene’’ is a
constant source of confusion and
obfuscation in biology and medicine
that requires remedy. We hope to offer
some concrete suggestions, however
difficult they may be to satisfy, becauseCell 155, Sincorrect knowledge is worse than no
knowledge at all (Brown and Goldstein,
1992).
Consider that two types of genomic
surveys, one horizontal and the other ver-
tical, are now routine for attempting to
understand human biology and disease.
In horizontal or broad surveys, we can
obtain the full genome sequence in tens
to hundreds of thousands of individuals
to sort out which genomic segments are
important and which are innocent
bystanders, to a particular comparison
between individuals, such as those with
versus without coronary artery disease
or cases with early versus late onset of
dementia. In contrast, in vertical or deep
surveys, we examine the effects of the
genome as the DNA information gets pro-
cessed, and its encoded functions get
executed through its transcriptome, pro-
teome, and effectors such as the metab-
olome. Both of these classes of studies
are relevant to analysis of a disease of
unknown etiology and have re-empha-
sized the long-held suspicion that study-
ing genes one-at-a-time may not be
meaningful because a gene’s effect is
usually pleiotropic, context dependent,
and contingent upon the state of many
other genetic and nongenetic factors
(Chin et al., 2012). In turn, this implies
that proving a gene’s specific role in a
biological process, either in wild-type or
mutant form, may not be straightforward
because its role may only be evident
when examined in relation to itseptember 26, 2013 ª2013 Elsevier Inc. 21
Box 1. Koch’s Postulates for Complex
Human Diseases and Traits
(1) Candidate gene variants are
enriched in patients.
(2) Disruption of the gene in amodel
system gives rise to a model
phenotype that is accepted as
relevant and ‘‘equivalent’’ to the
human phenotype.
(3) The model phenotype can
be rescued with the wild-type
human alleles.
(4) The model phenotype cannot be
rescued with the mutant human
alleles.biochemical partners, and in particular
contexts of diet, pathogen exposure,
etc. (Zerba et al., 1996). This is a partic-
ular problem in genetic studies of any
outbred nonexperimental organism,
such as the human, and studies of human
disease, where investigations are obser-
vational not experimental. It is the strong
belief of contemporary human geneticists
that uncovering the genetic underpin-
nings of any disease, however complex,
is the surest unbiased route to under-
standing its pathophysiology and, thus,
enabling its future rational therapies
(Brooke et al., 2008). Consequently, for
this view to prevail, we should require
experimental evidence, be it in cells, tis-
sues, experimental models, or the rare
patient, for the role of a specific gene in
a disease process. We discuss here the
types of evidence that we consider
incontrovertible.
Success in this difficult task requires us
to solve a logical conundrum: how can
we understand the genes underlying a
phenotype if some of these component
factors, in isolation, do not have recog-
nizable phenotypes on their own? We
know that even in a simple model organ-
ism, budding yeast, synthetic lethality—
where death or some other phenotype
occurs only through the conspiracy of
mutations at two different genes—is
widely prevalent (Costanzo et al., 2010).
Interactions of greater complexity and
involving more than two genes are also
known in yeast (Hartman et al., 2001)
and must be true for humans as well. A
human genome will typically harbor 20
genes that are fully inactivated, without22 Cell 155, September 26, 2013 ª2013 Elseany overt disease phenotype, presum-
ably due to the buffering by other genes
(MacArthur et al., 2012). Acknowledging
this complexity, there are two general
ways forward. First, at this stage of our
knowledge, perhaps we should not worry
about ‘‘all’’ of the genes in a disease, in
many ways an undefinable goal, but
rather those whose effects are demon-
strable, i.e., through a mutation that, irre-
spective of its interactions, can by itself
affect a critical pathway. Second, as we
unravel the effects of multiple genes on
a phenotype, we should advance the
same criterion, namely, that a set of
mutations affects that same critical pro-
cess. Both of these goals are approach-
able, particularly with recent advances
in genome-editing technologies that
allow the creation of multiple mutations
within a single experimental organism
(Wang et al., 2013). The question then is
how ‘‘complex’’ are complex traits and
diseases?
The New Genetics: Understanding
the Function of Variation
With the rediscovery of Mendel’s rules of
transmission more than 100 years ago,
there was a vicious debate on the
relative importance of single-gene versus
multifactorial inheritance (Provine, 1971).
Geneticists quickly, and successfully,
focused on deciphering the specific
mechanisms of gene inheritance and un-
derstanding the physiology of the gene
in lieu of answering why some pheno-
types had complex etiology and transmis-
sion. Nevertheless, the rare examples of
deciphering the genetic basis of complex
phenotypes, such as for truncate (wing) in
Drosophila (Altenburg and Muller, 1920),
clearly emphasized that traits were more
than the additive properties of multiple
genes. Today, it is quite clear that
Mendelian inheritance of traits, including
diseases, is the exception not the rule.
Nevertheless, the entire language of
genetics is in terms of individual genes
for individual phenotypes, with one
function, rather than the ensemble and
emergent properties of genomes. This
absence of a specific genetics language
for the proper description of the multi-
genic architecture of traits (the ensemble)
remains as an impediment to our under-
standing of the nature and degree of
genetic complexity of the phenotype.vier Inc.The case of amyotrophic lateral scle-
rosis (ALS), a devastating, progressive
motor neuron disease, illustrates this
point (Ludolph et al., 2012). Despite the
lack of evidence, we largely describe
ALS as being ‘‘heterogeneous’’ and
comprised of single-gene mutations that
can individually lead to disease. In
1993, mutations in superoxide dismutase
1 (SOD1) were identified in an auto-
somal-dominant form of the disease;
subsequently, the disorder has become
synonymous with aberrant clearance of
free radicals as its central pathology.
What is often not appreciated, however,
is that fewer than 10% of all cases of
ALS are familial and even fewer follow
an apparent Mendelian pattern. Even
within this subset of cases, more than
20 distinct genes, spanning other path-
ways including RNA homeostasis, have
been identified, and SOD1 represents a
minority of cases. The molecular etiology
for the majority of the sporadic forms of
the disease remains unclear, and the sci-
entific problem in understanding ALS is
more than simply identification of addi-
tional genes. We may ask, can SOD1
and the other described gene mutations
lead to ALS by themselves? Are these
the key rate-limiting steps to ALS or sim-
ply one of several required in concert? Is
the aberrant clearance of free radicals
the fundamental defect or one of many
such pathologies or a common down-
stream consequence? Given the diver-
sity and number of deleterious, even
loss-of-function, genetic variants in all
of our genomes (Abecasis et al., 2012;
MacArthur et al., 2012) and, in the
absence of stronger evidence bearing
on these questions, it is fair to assume
that ALS patients harbor multiple muta-
tions with a plurality of molecular defects
and that free radical metabolism is only
one of a set of canonical pathophysiol-
ogies that define the disease. No doubt,
this plurality is the case for cancer (Vo-
gelstein et al., 2013), Crohn’s disease
(Jostins et al., 2012), and even rare
developmental disorders such as Hirsch-
sprung disease (McCallion et al., 2003).
In all of these cases, a richer genetics
vocabulary may improve our understand-
ing of the phenotypes through recog-
nizing what we know and what we
don’t; our current language limits us to
describing genes not phenotypes.
Molecular biology, genetics’ twin, on
the other hand, appears to have been far
more successful in deciphering and
describing not only its individual compo-
nents (e.g., DNA, RNA, protein) but also
their mutual relationships (e.g., DNA-
protein interaction) and ensembles (e.g.,
transcriptional complex), although this is
also far from complete (Watson et al.,
2007). Not only do we understand the
structure of individual genes and how
their molecular functions get executed,
but we are also starting to learn how
functions get regulated through a diversity
of cis- and trans-acting functions. The
consequences of the primary and interac-
tion effects are often well understood,
even though not completely described,
at both the molecular and cellular levels
(Alberts et al., 2007). There are also
improving technologies and understand-
ing of the structures and functions of
ensembles of proteins and cells, and
how these interact and communicate
with one another to create complexity
(Ilsley et al., 2013). Although the use of
genetic tools and genetic perspectives
are fundamental to this progress, these
advances have not as yet led to a major
revision of our understanding of trait or
disease variation. The major reason for
this discrepancy is that, with few excep-
tions (Raj et al., 2010), molecular and cell
biology has focused on the impact of
deleting or overexpressing genes and
not grappled with the consequences of
allelic variation.
Classical Mendelian genetics has been
a boon to uncovering biology from yeast
to humans whenever a mutation with a
simple inheritance pattern can be iso-
lated. This approach has been revolution-
ary in the unicellular yeast, particularly
because genetics (and gene manipula-
tion), biochemistry, and cell biology were
melded to understand function at a variety
of levels. This kind of multilevel approach
has been less straightforward, but still
largely successful, for a metazoan such
asDrosophilawheremore genes andmul-
tiple specialized cells often rescue the
effects of a mutation or enhance its minor
effect. These lessons suggest to us that
the current approach, based strictly on
genetic variation, to understanding com-
plex human disease is also grossly insuffi-
cient and, as in yeast and flies, will require
the contemporaneous analysis of themolecular biology, biochemistry, and
physiology of the genes within a mapped
locus to even identify the disease gene,
let alone understand its functions. Suc-
cess in this endeavor will require a synthe-
sis of many biological disciplines that
includes the role of genetic variation as
intrinsic to the biological process, not an
aspect to be ignored.
Consequently, melding variation-based
genetic and molecular biological thinking
is of critical importance for both fields
and is central to our understanding of
mechanisms of trait variation, including
interindividual variation in disease risk. If
most disease, in most humans, is the
consequence of the effects of variation
at many genes, then knowledge of their
functional relationships, rather than
merely their identities, is central to under-
standing the phenotype. This is clearly a
problem of ‘‘Systems Biology’’ but one
that incorporates genetic variation
directly. The ability to integrate the real-
ities of such widespread genetic variation,
which are ultimately at the causal root
of disease mechanisms, with systems
biology approaches to understand func-
tional contingencies is central to the
challenge of deciphering complex human
disease. Importantly, it is likely to spur
new thinking in both fields.
Genetic Dissection of Complex
Phenotypes
Genetic transmission rules imply that,
even in an intractable species such as
us, one can map genomic segments that
must contain a disease or trait gene. The
lure and success of this method is that
we can map a disease locus in the
absence of any knowledge of the underly-
ing biology of the phenotype. Such
mapping requires identification of the
segregation of common sites of variation
across the genome, now easy to identify
through sequencing, and recognition of
a genomic segment identical-by-descent
in affected individuals, both within and
between families. This task has become
easier and more powerful as sequencing
technology has improved to provide a
nearly complete catalog of variants above
1% frequency in the population; further
improvements to sample rarer variants
are ongoing (Abecasis et al., 2012).
Consequently, genetic mapping, once
the province of rare Mendelian disorders,Cell 155, Sis now applicable to any human trait or
disease. In fact, more than 2,000
confirmed loci, each containing multiple
genes, affecting susceptibility to more
than 100 medically relevant traits (e.g.,
blood pressure) and disease (e.g., hyper-
tension) are now known (Hindorff et al.,
2009). For most complex traits examined,
many such loci have been mapped, but
the vast majority of the specific genes
remain unidentified. We can sometimes
guess at a candidate gene within the lo-
cus (Jostins et al., 2012), sometimes
implicate a gene by virtue of an abun-
dance of rare variants among affected
individuals (Jostins et al., 2012), in rare
circumstances, use therapeutic modula-
tion of a pathway to pinpoint the gene
(Moon et al., 2004), and sometimes
identify one by painstaking experimental
dissection (Musunuru et al., 2010), but,
generally, identification of the underlying
gene has not become easier. In fact,
most of the mapped loci underlying com-
plex traits remain unresolved at the gene
or mechanistic level.
Despite the beginning clues to human
disease pathophysiology that complex
disease mapping is providing, and the
slow identification of individual genes, it
appears highly unlikely that we can
understand traits and diseases this way.
There is indeed evidence for scenarios
in which variation in complex traits,
including risk of complex disease, is
mediated by a myriad of variants of
minute effect, spread evenly across the
genome (Yang et al., 2011). Therefore,
we need other approaches to override
this bottleneck.
For Mendelian disorders, gene identifi-
cation within a locus is made possible by
each mutation being necessary and suffi-
cient for the phenotype, being functionally
deleterious and rare, and having an inher-
itance pattern consistent with the pheno-
type. It’s the mutation that eventually
reveals the biology and explains the
phenotype. Any component locus for a
complex disease has no such restriction,
as the causal variants are neither neces-
sary nor sufficient, nor coding (in fact,
they are frequently noncoding and regula-
tory) nor rare (Emison et al., 2010; Jostins
et al., 2012). Currently, the major attempts
to overcome this impediment involve reli-
ance on single severe mutations at the
very same component genes andeptember 26, 2013 ª2013 Elsevier Inc. 23
Figure 1. Complementary Approaches Necessary for Proving Genetic Causality and
Understanding the Pathophysiology of Complex Disease
Genetic association studies in humans can synergize with prior knowledge and systems-level quantitative
analysis to generate predictions of what pathways and modules are disrupted, where (anatomically), and
when (developmentally) to yield a specificmorphological or biochemical phenotype. These predictions can
then be tested in an appropriate model system while adhering to the postulates outlined in Box 1.demonstrating Mendelian inheritance of
the same or similar phenotype, and/or
identifying single genes with a demon-
strable excess of rare coding variants.
The first of these two strategies is a strong
unproven hypothesis and probably not
universally true, whereas the second re-
lies on very large sample sizes of patients
and suffers from the unknown functional
effect of the majority of rare coding vari-
ants. Consequently, these strategies
themselves depend on the hidden biology
we seek and are applicable only to the
most common human diseases. It ap-
pears to us that ignorance of biology has
become rate limiting for understanding
disease pathophysiology, except perhaps
for the Mendelian disorders. There are
two ways to get out of this vicious cycle
(Figure 1).
One approach may be to use a set of
model traits and diseases and employ
their existing mapped loci to identify a
small set of the component genes by
brute-force (or, luck) and use the uncov-
ered biology to infer which other genes
in their ‘‘pathways’’ can explain the dis-24 Cell 155, September 26, 2013 ª2013 Elseease. This approach has been highly prof-
itable in Crohn’s disease—a common
inflammatory disorder whose root causes
remained cryptic until genome-wide
association studies identified a large
number of loci with fundamental defects
in mucosal immunity (Graham and Xavier,
2013)—but not in type 2 diabetes, where
the pathophysiology awaits clarification
(Groop and Pociot, 2013). Although we
suspect that the numbers of pathways
involved are fewer than the numbers of
genes involved, this is merely suspicion.
Nevertheless, can we reduce the com-
plexity of the problem by identifying all
of the relevant pathways? Despite uncer-
tainty, this approach has the advantage of
leading to specific testable hypotheses.
The second approach is to focus research
on why the disease is complex in the first
place. Although the genome is linear, its
expression and biology are highly
nonlinear and hierarchical, being seques-
tered in specific cells and organelles
(Ilsley et al., 2013). Understanding this
hierarchy, the province of systems
biology, is critical to the solution of thevier Inc.complex inheritance problem (Yosef
et al., 2013). Even more importantly, this
approach might, through the effect of
mutations, allow us to decipher cell cir-
cuitry and understand which pathways
are limiting and which are redundant.
This last aspect is critical: as we argue
below, with our current state of knowl-
edge, we are likely to have our greatest
success with understanding how genes
map onto pathways, and how pathways
map onto disease, before a true quantita-
tive understanding of disease biology
emerges. One might counter that existing
gene ontologies do precisely that, but,
even in yeast, this appears to be highly
incomplete (Dutkowski et al., 2013).
Proving Causality: Molecular
Koch’s Postulates
The evidence that a specific gene is
involved in a particular human disease
has historically been nonstatistical and
based on our experience with identifying
mutations in Mendelian diseases. The
chief criteria have been to demonstrate
cosegregation with the phenotype in
families, exclusivity of the mutation to
affected individuals (rare alleles absent
in controls), and the nature of themutation
(a plausibly deleterious allele at a
conserved site within a protein). Unfortu-
nately, as already mentioned, all of these
rules break down in complex phenotypes
where neither cosegregation nor exclu-
sivity to affecteds nor obviously delete-
rious alleles are likely; moreover, many
mutations are suspected to be noncoding
and in a diversity of regulatory RNA mole-
cules. Consequently, statistical evidence
of enrichment has been the mainstay,
but this has two negative consequences:
first, scanning across the genome or
multiple loci covering tens to hundreds
of megabases requires very large sample
sizes and very strict levels of significance
to guard against themany expected false-
positive findings; second, genetic effects
that are small or genes with only a few
causal alleles are notoriously difficult to
detect, although they may be very impor-
tant to understanding pathogenesis. This
difficulty translates into a low power of
detection, as common disease alleles
cannot be distinguished from bystander
associated alleles, whereas rare alleles
are observed too infrequently to provide
statistical significance. Consequently,
although many genes are ‘‘named’’ as
being responsible in a complex disease
or disease process, proof of their involve-
ment is either absent or circumstantial
and not direct.
We need to move beyond lists of plau-
sible genes, to provide rigorous proof for
their role in disease. In the late 19th cen-
tury when bacteria were first shown to
cause human disease, they were indis-
criminately implicated in all manner of
disease with little proof (Brown and Gold-
stein, 1992). One particularly embarrass-
ing example was alcaptonuria, which Sir
Archibald Garrod subsequently showed
was inherited and which was his first
‘‘inborn error of metabolism.’’ We are
likely to repeat this ‘‘witch-hunt’’ unless
we are careful to note that mapping a
locus is not equivalent to identifying the
gene, and that identifying a gene and its
mutations at a locus depends on
numerous untested assumptions (muta-
tional type, mutational frequency in cases
and controls, coding or regulatory, cell
autonomy). So what might be rigorous
proof of an attractive candidate? Inmicro-
biology, Robert Koch set out three postu-
lates that had to be satisfied to connect a
specific bacterium (among the multitudes
encountered, not unlike current genome
analysis) to a disease: the agent had to
be isolated from an affected subject, the
agent had to produce disease when
transmitted to an animal, and the agent
had to be recoverable from an animal’s
lesion (Falkow, 1988). For any human dis-
easewheremany loci have beenmapped,
we can propose analogous postulates: (1)
a specific candidate gene identified by
mapping with variants is enriched in pa-
tients, (2) demonstration of a mutant
phenotype among bearers of mutations
in the same gene in a ‘‘model system,’’
(3) rescue of the mutant phenotype using
wild-type human alleles, and (4) failure to
rescue the mutant phenotype using hu-
man mutant alleles. In principle, these
are applicable to both single genes and
collections of a few genes (Wang et al.,
2013). The key to these analyses is the
equivalence of the laboratory model
phenotype; this cannot be arbitrary but
one carefully chosen to be analogous to
the human phenotype. In other words,
we require success at two levels: demon-
stration that amutant allele leads to a spe-
cific mutant phenotype in a model systemand demonstration and acceptance that
the model and human phenotypes are
equivalent.
The keys to these analyses are delinea-
tion of the terms ‘‘model system’’ and
‘‘phenotype.’’ First, many types of re-
agents could comprise the ‘‘model sys-
tem,’’ including human cells and tissues,
animal models, and human volunteers in
rare circumstances (e.g., therapeutic in-
terventions against a pathway). Eventu-
ally, even computational models of tissue
physiology, such as for the cardiac system
(Guyton et al., 1972), might be helpful.
Second, many types of phenotypes could
be considered from a biochemical or
cellular correlate of the disease to an anal-
ogous pathology in animal model sys-
tems. Simply because we cannot follow
Koch to the letter in human patients does
not absolve us from the responsibility of
demonstrating a rigorous level of proof.
This is particularly true if we are to pursue
therapeutic targets for these diseases.
It is clear that the majority of complex
diseases do not harbor this level of proof
today; neither do most monogenic disor-
ders. As the case for Marfan syndrome
demonstrates, the identification of fibrillin
1 mutations was insufficient to identify
therapies without the concomitant under-
standing of the pathophysiology (Brooke
et al., 2008). Animal models are attractive
because of the ability to do experimental
manipulations that test predictions of
gene function, but these experiments
test the function of a gene in a context
that is decidedly different from that with
a human patient. However imperfect ani-
mal models are, progress in the direction
of understanding causality has been very
beneficial when gene disruptions alone,
perhaps at more than one gene, have
taught us fundamental lessons in patho-
physiology (Farago et al., 2012). In many
cases, investigators have also demon-
strated that disease results only when
combined with a potent environmental
insult. When known, such as the effect
of dietary cholesterol vis-a`-vis genes
involved in cholesterol metabolism in
atherosclerosis, such environmental ex-
posures to gene-deficient mouse models
have provided a tight circle of proof
(Plump et al., 1992). A recent example of
gestational hypoxia modulating the effect
of Notch signaling and leading to
scoliosis in mice and in human familiesCell 155, Sshows how environmental factors beyond
diet can be examined even for congenital
disorders (Sparrow et al., 2012). Despite
these successes, pursuit of Koch’s
postulates faces other challenges. For
example, mutations in the same gene
might not reveal an identical phenotype
in humans and in an animal model
even if molecular pathways are con-
served. This is a particular problem for
behavioral phenotypes where brain cir-
cuitry may have evolved quite differently
in humans and other mammals, chal-
lenging our ability to model behavior
accurately. Nevertheless, such an anal-
ysis might reveal an underlying neural
phenotype or a molecular or cellular
correlate that is in common and subject
to testing of the postulates.
Ultimately, a lack of understanding of
fundamental physiology is the biggest
impediment to our understanding of
genetically complex human disease. A
unique aspect of genetics research
seldom appreciated is that genetic effects
are chronic biological exposures and as
such can pinpoint the earliest stages of
disease not readily studied otherwise. To
fulfill this potential contribution of genetics
to physiology, genetic studies that can
inform disease pathogenesis should be
intrinsic to additional mapping. In reality,
we still do not fully understand the patho-
genesis stemming from some of the
earliest identified human disease genes.
With better understanding of disease
mechanism, it seems likely that many dis-
orders that we think of as ‘‘genetic’’ may
have ameliorative diet, exercise, or other
benign environmental ‘‘treatments.’’ But
this goal is unlikely to be achieved in the
absence of a superior understanding of
the biology of hierarchical function within
genomes, how variation alters these
functions, and how these altered functions
lead to human disease. Koch’s postulates
canbeaguiding light for thesediscoveries.
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